Vertex Raises 2026 Revenue Outlook To $13.15 Billion To $13.25 Billion After Closing Crinetics Deal

Third-quarter sales rose 12% to $3.44 billion, while net income fell to $653.6 million on costs tied to the Crinetics purchase.

Share
Vertex Raises 2026 Revenue Outlook To $13.15 Billion To $13.25 Billion After Closing Crinetics Deal

Vertex Pharmaceuticals, the biotech behind cystic fibrosis medicines, the gene-editing therapy Casgevy and the pain drug Journavx, raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion, from $13.1 billion to $13.2 billion, the company said Monday. Third-quarter revenue rose 12% to $3.44 billion, but net income fell to $653.6 million as the Crinetics Pharmaceuticals acquisition added costs.

Sales up, profit down on deal costs

GAAP net income, the standard-accounting measure, was $653.6 million, or $2.56 a diluted share, against $1.08 billion, or $4.20, a year earlier. The company said the decline stemmed primarily from expenses related to the Crinetics acquisition, including about $500 million of compensation and transaction costs.

On an adjusted basis, net income was $1.2 billion in both quarters, or $4.76 a share versus $4.80. Higher product revenue was offset by greater operating spending and more interest expense, the company said.

U.S. revenue rose 10% to $2.17 billion, and revenue outside the U.S. rose 16% to $1.27 billion. Vertex raised its combined GAAP research, acquired research and sales and administrative expense guidance to $7.15 billion to $7.2 billion, from $6.3 billion to $6.45 billion.

Casgevy and Journavx scale up

Casgevy revenue reached $99 million in the quarter, up 30% from the prior quarter and nearly six times the $17 million a year earlier. Journavx brought in $58 million, nearly triple the $20 million of the third quarter of 2025, and more than 750,000 prescriptions were filled.

The new outlook assumes $500 million or more from Casgevy and Journavx combined. It also assumes $40 million to $50 million from Palsonify, the acromegaly drug that came with Crinetics, which brought in $10 million in September.

CEO Reshma Kewalramani said the company is "well positioned to establish nephrology as our fifth commercial franchise."

Cash drawn down, kidney decision looms

Vertex closed the Crinetics purchase on September 1 at an equity value of about $10.0 billion, or $9.0 billion net of cash acquired. It borrowed $4.5 billion through a term loan, and cash and marketable securities fell to $9.8 billion from $12.3 billion at the end of 2025.

The FDA has set a target action date of November 30 for povetacicept, Vertex's treatment for IgA nephropathy, a kidney disease. If approved, it would be the first product in Vertex's nephrology franchise.

The FDA's November 30 target date for povetacicept is the next marker for Vertex's kidney ambitions.

Sources

More on Vertex Pharmaceuticals

All Vertex Pharmaceuticals (VRTX) coverage →